Home › Research › Risk factors
Social determinants of pharmacological dementia management: results from IDEAS
Margo B. Heston, Charles Windon, Lucy S. Hanna, Constantine Gatsonis, Marı́a C. Carrillo, Charles E. Apgar, Peggye Dilworth‐Anderson, Bruce E. Hillner et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Risk, prevention and care in population studies
Plain-language summary
We used multilevel logistic regression with a random site intercept to test whether the probability of change in management associated with social determinants, race/ADI interactions with amyloid‐positivity, comorbidities, and clinical setting, adjusting for demographics. Results Among 10,904 cognitively impaired participants (Table 1), 90% were White, with 4.8% Hispanic, 3.1% Black, and 1.8% Asian representation. 10% resided in highly disadvantaged neighborhoods (ADI 9‐10), 83% lived with ≥1 person, and 68% were educated past high school. Pre‐FDR correction (adjusted P ‐values: Table 1), AD drug management change was associated with dyslipidemia (OR [95% CI]=0.88 [0.80‐0.97], P unadj =.007), depression (0.87 [0.77, 0.97], P unadj =.014), and tobacco use (0.87 [0.77, 0.99], P unadj =.028). Non‐AD drug management change was associated with depression (1.73 [1.51, 1.97], P unadj <.001), group practice (0.72 [0.56, 0.93], P unadj =.012) and ADI in amyloid‐positive participants (0.68 [0.47, 0.98], P unadj =.04). Change rates were also associated with amyloid‐PET status, impairment level, and etiology. Conclusions These results suggest amyloid status, cognitive impairment level, dementia etiology, and comorbidities may inform pharmacological decision‐making.
What this study adds
Evidence grade: Low
The study is about factors linked to medication management decisions, not about whether any treatment cures or prevents Alzheimer's disease. Reported effect size: 4.8%; 3.1%; 1.8%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Heston, M. B., Windon, C., Hanna, L. S., Gatsonis, C., Carrillo, M. C., Apgar, C. E., et al. (2025). Social determinants of pharmacological dementia management: results from IDEAS. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_107370
Vancouver
Heston MB, Windon C, Hanna LS, Gatsonis C, Carrillo MC, Apgar CE, et al. Social determinants of pharmacological dementia management: results from IDEAS. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_107370. PMID: 41518511.
BibTeX
@article{heston2025-41518511,
author = {Heston, Margo B. and Windon, Charles and Hanna, Lucy S. and Gatsonis, Constantine and Carrillo, Marı́a C. and Apgar, Charles E. and Dilworth‐Anderson, Peggye and Hillner, Bruce E. and others},
title = {{Social determinants of pharmacological dementia management: results from IDEAS}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_107370},
pmid = {41518511},
url = {https://doi.org/10.1002/alz70856_107370}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We used multilevel logistic regression with a random site intercept to test whether the probability of change in management associated with social determinants, race/ADI interactions with amyloid‐positivity, comorbidities, and clinical setting, adjusting for demographics.
- Results Among 10,904 cognitively impaired participants (Table 1), 90% were White, with 4.8% Hispanic, 3.1% Black, and 1.8% Asian representation. 10% resided in highly disadvantaged neighborhoods (ADI 9‐10), 83% lived with ≥1 person, and 68% were educated past high school.
- Pre‐FDR correction (adjusted P ‐values: Table 1), AD drug management change was associated with dyslipidemia (OR [95% CI]=0.88 [0.80‐0.97], P unadj =.007), depression (0.87 [0.77, 0.97], P unadj =.014), and tobacco use (0.87 [0.77, 0.99], P unadj =.028).
- Non‐AD drug management change was associated with depression (1.73 [1.51, 1.97], P unadj <.001), group practice (0.72 [0.56, 0.93], P unadj =.012) and ADI in amyloid‐positive participants (0.68 [0.47, 0.98], P unadj =.04).
- Change rates were also associated with amyloid‐PET status, impairment level, and etiology.
Why it matters
Among 10,904 cognitively impaired participants, changes in AD drug management were associated with dyslipidemia, depression, and tobacco use, and changes in non-AD drug management were associated with depression, group practice, and area deprivation index in amyloid-positive participants. The study is about factors linked to medication management decisions, not about whether any treatment cures or prevents Alzheimer's disease.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Effect size4.8%; 3.1%; 1.8%
- Evidence strengthLow
How this study scored 40/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Gil D. Rabinovici: h-index 116 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41518511) |
| Free to read | 2 / 2 | Free to read |
| Total | 40 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70856_107370
- PubMed: 41518511
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Risk factors from nearby years
Also tagged “prevalence”
1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.